Hjem › Ikke-småcellet lungekreft › Massachusetts › Springfield
Kliniske studier for Ikke-småcellet lungekreft i Springfield, MA
4 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Springfield (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Baystate Medical Center, Springfield
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Baystate Medical Center, Springfield
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Baystate Medical Center, Springfield
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Baystate Medical Center, Springfield
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY120 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH56 studier
- Washington, DC55 studier
Andre studier i Springfield
- Eggstokkreft5 studier
- Lungekreft5 studier
- Makuladegenerasjon4 studier
- Opioidoverdose3 studier
- Melanom3 studier
- Endometriekreft3 studier
- Koronararteriesykdom3 studier
- Major depresjon3 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.